Balaxi Pharmaceuticals Ltd
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]
- Market Cap ₹ 300 Cr.
- Current Price ₹ 54.4
- High / Low ₹ 133 / 49.2
- Stock P/E 12.0
- Book Value ₹ 42.0
- Dividend Yield 0.00 %
- ROCE 12.5 %
- ROE 11.6 %
- Face Value ₹ 2.00
Pros
Cons
- Company has a low return on equity of 3.81% over last 3 years.
- Debtor days have increased from 93.1 to 138 days.
- Promoter holding has decreased over last 3 years: -6.87%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 14 | 46 | 231 | 279 | 336 | 241 | 293 | |
| 12 | 37 | 189 | 229 | 279 | 197 | 255 | |
| Operating Profit | 2 | 8 | 43 | 51 | 57 | 45 | 37 |
| OPM % | 11% | 18% | 18% | 18% | 17% | 18% | 13% |
| 1 | 1 | 2 | 5 | 3 | -38 | -4 | |
| Interest | 0 | 0 | 0 | 1 | 1 | 3 | 3 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
| Profit before tax | 2 | 9 | 44 | 55 | 57 | 2 | 29 |
| Tax % | 19% | 31% | 14% | 13% | 19% | 219% | 13% |
| 2 | 6 | 38 | 48 | 46 | -2 | 25 | |
| EPS in Rs | 1.30 | 1.22 | 7.63 | 9.53 | 9.03 | -0.44 | 4.54 |
| Dividend Payout % | 0% | 0% | 0% | 1% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 45% |
| 3 Years: | 2% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | -19% |
| TTM: | 150% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | -8% |
| 1 Year: | -57% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 4% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 10 | 10 | 10 | 10 | 11 | 11 |
| Reserves | 0 | 18 | 55 | 103 | 173 | 190 | 221 |
| 0 | 0 | 4 | 4 | 13 | 19 | 53 | |
| 3 | 8 | 31 | 60 | 43 | 38 | 25 | |
| Total Liabilities | 6 | 36 | 100 | 176 | 240 | 258 | 310 |
| 0 | 0 | 2 | 29 | 41 | 41 | 41 | |
| CWIP | 0 | 0 | 0 | 1 | 3 | 2 | 22 |
| Investments | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| 6 | 36 | 94 | 147 | 195 | 215 | 247 | |
| Total Assets | 6 | 36 | 100 | 176 | 240 | 258 | 310 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| -2 | -14 | 0 | 34 | 6 | 5 | -35 | |
| -0 | -0 | -6 | -28 | -11 | -1 | -22 | |
| 0 | 18 | 4 | -0 | 26 | 30 | 34 | |
| Net Cash Flow | -2 | 4 | -2 | 6 | 21 | 34 | -23 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 147 | 238 | 121 | 36 | 57 | 84 | 138 |
| Inventory Days | 9 | 29 | 184 | 189 | 233 | 173 | |
| Days Payable | 64 | 53 | 92 | 62 | 82 | 36 | |
| Cash Conversion Cycle | 147 | 183 | 97 | 129 | 184 | 235 | 275 |
| Working Capital Days | 82 | 181 | 96 | 97 | 133 | 168 | 224 |
| ROCE % | 57% | 93% | 60% | 37% | 21% | 12% |
Documents
Announcements
-
Investor Presentation
7 June 2025 - Balaxi reports 21% revenue growth, 915 products, and new Hyderabad pharma plant commissioning Q1 FY26.
-
Copy of Newspaper Publication
31 May 2025 - Balaxi Pharmaceuticals publishes audited Q4 and FY25 financial results and dividend declaration.
-
Disclosure under SEBI Takeover Regulations
30 May 2025 - BALAXI Overseas Pvtﾠ LIMITEDﾠhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, …
-
Disclosure under SEBI Takeover Regulations
30 May 2025 - BALAXI Overseas Private LIMITEDﾠhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, …
-
Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
30 May 2025 - BALAXI PHARMACEUTICALS LIMITED has informed about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
Annual reports
Concalls
-
Jun 2025TranscriptNotesPPT
-
Feb 2025TranscriptNotesPPT
-
Nov 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022TranscriptPPT
-
Nov 2022Transcript PPT
-
Oct 2022TranscriptNotesPPT
-
Aug 2022TranscriptPPT
-
Aug 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022TranscriptNotesPPT
-
Jun 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Jul 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Oct 2020TranscriptNotesPPT
Product Portfolio
The company is a branded IPR-based pharmaceutical player focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs across multiple therapeutic segments. As of 9M FY25, it has a portfolio of 897 registered products across 7 countries in Africa and Latin America serving through 38 warehouses. [1] [2] [3]